专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL292588A Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers 未知
公开(公告)号：IL292588A
公开(公告)日：2022-06-01
申请号：IL29258822
申请日：2022-04-27
申请人： ALCEDIAG , WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
发明人： WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
摘要： The present invention is drawn to a method for in vitro for differential diagnosing bipolar disorder and unipolar depression in a human patient from a biological sample of said patient, using at least one or a combination of particular A to I editing RNA biomarkers associated to a specific depression score and algorithm. The present invention is also directed to a method for diagnosing bipolar disorder implemented the particular combination of A to I editing RNA biomarkers associated to a specific depression score and algorithm of the present invention. The present invention is also directed to a method for monitoring treatment for bipolar or unipolar disorder, said method implementing the method for differential diagnosing bipolar disorder and unipolar depression of the present invention. Kit for determining whether a patient presents a bipolar disorder versus unipolar depression disorder or healthy control patient is also comprised in the present invention.

2. 发明专利

IL261579D0 Algorithm and an in vitro method based on rna editing to select particular effect induced by active compounds 未知
公开(公告)号：IL261579D0
公开(公告)日：2018-10-31
申请号：IL26157918
申请日：2018-09-04
申请人： CENTRE NAT RECH SCIENT , ALCEDIAG , WEISSMANN DINAH , VAN DER LAAN SIEM , SALVETAT NICOLAS , MOLINA FRANCK , PUJOL JEAN FRANCOIS
发明人： WEISSMANN DINAH , VAN DER LAAN SIEM , SALVETAT NICOLAS , MOLINA FRANCK , PUJOL JEAN-FRANCOIS
IPC分类号： C12Q20060101
摘要： The present invention is drawn to an algorithm and method using the same algorithm for in vitro predicting the probability of a drug or a compound to induce a particular effect in a patient, said method using at least one target exhibiting an A-to-I editing of RNA. The present invention also relates to kits for the implementation of the method.

3. 发明专利

IL292587D0 Diagnosing of mood disorders using blood rna editing biomarkers 未知
公开(公告)号：IL292587D0
公开(公告)日：2022-06-01
申请号：IL29258722
申请日：2022-04-27
申请人： ALCEDIAG , WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
发明人： WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
IPC分类号： G16B20/00 , G16B40/20
摘要： The present invention is drawn to a method for in vitro diagnosing mood disorders particularly depression disorders, more preferably major depressive disorder (MDD) in a human patient from a biological sample of said patient, using at least one or a combination of particular A to I editing RNA biomarkers associated to a specific depression score and algorithm. The present invention is also directed to a method for monitoring treatment for mood disorders in a human subject, preferably for monitoring depression and MDD, said method implementing the method for diagnosing mood disorders of the present invention. Kit for determining whether a patient presents a mood disorder, preferably depression disorder, more preferably MDD, is also comprised in the present invention.

4. 发明专利

IL292588D0 Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers 未知
公开(公告)号：IL292588D0
公开(公告)日：2022-06-01
申请号：IL29258822
申请日：2022-04-27
申请人： ALCEDIAG , WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
发明人： WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
IPC分类号： G16B20/00 , G16B40/20
摘要： The present invention is drawn to a method for in vitro for differential diagnosing bipolar disorder and unipolar depression in a human patient from a biological sample of said patient, using at least one or a combination of particular A to I editing RNA biomarkers associated to a specific depression score and algorithm. The present invention is also directed to a method for diagnosing bipolar disorder implemented the particular combination of A to I editing RNA biomarkers associated to a specific depression score and algorithm of the present invention. The present invention is also directed to a method for monitoring treatment for bipolar or unipolar disorder, said method implementing the method for differential diagnosing bipolar disorder and unipolar depression of the present invention. Kit for determining whether a patient presents a bipolar disorder versus unipolar depression disorder or healthy control patient is also comprised in the present invention.

5. 发明专利

IL292587A Diagnosing of mood disorders using blood rna editing biomarkers 未知
公开(公告)号：IL292587A
公开(公告)日：2022-06-01
申请号：IL29258722
申请日：2022-04-27
申请人： ALCEDIAG , WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
发明人： WEISSMANN DINAH , SALVETAT NICOLAS , CHIMIENTI FABRICE
摘要： The present invention is drawn to a method for in vitro diagnosing mood disorders particularly depression disorders, more preferably major depressive disorder (MDD) in a human patient from a biological sample of said patient, using at least one or a combination of particular A to I editing RNA biomarkers associated to a specific depression score and algorithm. The present invention is also directed to a method for monitoring treatment for mood disorders in a human subject, preferably for monitoring depression and MDD, said method implementing the method for diagnosing mood disorders of the present invention. Kit for determining whether a patient presents a mood disorder, preferably depression disorder, more preferably MDD, is also comprised in the present invention.

6. 发明专利

IL264377D0 Rna editing as biomarkers for mood disorders test 未知
公开(公告)号：IL264377D0
公开(公告)日：2019-02-28
申请号：IL26437719
申请日：2019-01-21
申请人： WEISSMANN DINAH , VAN DER LAAN SIEM , SALVETAT NICOLAS , PUJOL JEAN FRANCOIS , ALCEDIAG , VIRE BERANGERE
发明人： WEISSMANN DINAH , VAN DER LAAN SIEM , SALVETAT NICOLAS , PUJOL JEAN-FRANCOIS , VIRE BERANGERE
IPC分类号： C12Q20060101
摘要： The present invention is drawn to a method for in vitro predicting the risk for a patient to present a pathology or to identify whether a patient is at risk to develop a pathology, such as psychiatric disorder, associated to an alteration of A-to-I editing on PDE8A transcripts, from body fluids such as a blood, urine or saliva sample of said patient. The present invention also relates to kits for the implementation of the method.

7. 发明申请

WO2010070074A3 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 审中-公开
标题翻译：评估药物诱发的情绪失调和自杀的潜在风险：使用专用平台
公开(公告)号：WO2010070074A3
公开(公告)日：2010-10-07
申请号：PCT/EP2009067464
申请日：2009-12-17
申请人： BIOCORTECH , WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
发明人： WEISSMANN DINAH , PUJOL JEAN-FRANCOIS , VINCENT LAURENT , CAVAREC LAURENT
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.
摘要翻译：本发明涉及用于测定测试化合物的潜在毒性的体外方法。本发明还包括用于选择治疗化合物的体外方法，所述治疗化合物用于治疗与改变ADAR依赖性A至I mRNA编辑血清素2C受体（5HTR2C）的mRNA编辑机制有关的病理学。最后，本发明针对用于实施这些方法的试剂盒和工具。本发明在制药工业中用于分析药物开发中涉及的化合物和/或药物组合物的毒性分布或筛选方面是特别有用的。

8. 发明申请

WO2010070074A2 EVALUATION OF THE POTENTIAL RISK OF DRUG INDUCED MOOD DISTURBANCE AND SUICIDE: USE OF A DEDICATED PLATFORM 审中-公开
标题翻译：评估药物诱发的肌肉障碍和副作用的潜在风险：使用专用平台
公开(公告)号：WO2010070074A2
公开(公告)日：2010-06-24
申请号：PCT/EP2009/067464
申请日：2009-12-17
申请人： BIOCORTECH , WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent
发明人： WEISSMANN, Dinah , PUJOL, Jean-François , VINCENT, Laurent , CAVAREC, Laurent
IPC分类号： C12Q1/68 , G01N33/573
CPC分类号： C12Q1/6881 , C12Q1/6883 , C12Q2600/142 , C12Q2600/158 , G01N33/5014 , G01N33/5058 , G01N33/942 , G01N2800/302 , G01N2800/303 , G01N2800/304
摘要： The present invention relates to in vitro methodsfor the determination of the potential toxicity of test compounds. The invention also comprises in vitro methods for the selection of therapeutical compounds useful for the treatment of pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing of the serotonin 2C receptor (5HTR2C). Finally, the present invention is directed to the kits and tools for the implementation of these methods. The invention is of special utility in the pharmaceutical industry for analysis of the toxicity profile or the screening of compounds involved in drug development and/or in pharmaceutical compositions.
摘要翻译：本发明涉及测定化合物潜在毒性的体外方法。本发明还包括用于选择治疗化合物的治疗化合物的方法，所述治疗化合物可用于治疗与改变血清素2C受体（5HTR2C）的ADAR依赖性A至I mRNA编辑的mRNA编辑机制相关的病理学。最后，本发明涉及用于实施这些方法的套件和工具。本发明在制药工业中用于分析涉及药物开发和/或药物组合物的化合物的毒性特征或筛选。

9. 发明申请

WO2005103047A1 DERIVES DU 14.15-DIHYDRO 20.21-DINOREBURNAMENIN-14-OL, ET LEURS APPLICATIONS 审中-公开
标题翻译： 14.15-二氢O O O O O IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN IN OF OF OF OF OF OF OF OF OF OF OF OF OF OF
公开(公告)号：WO2005103047A1
公开(公告)日：2005-11-03
申请号：PCT/FR2005/000902
申请日：2005-04-14
申请人： BIOCORTECH , CIAPETTI, Paola , DEYON, Laurence , WERMUTH, Camille-Georges , PUJOL, Jean-François , WEISSMANN, Dinah
发明人： CIAPETTI, Paola , DEYON, Laurence , WERMUTH, Camille-Georges , PUJOL, Jean-François , WEISSMANN, Dinah
IPC分类号： C07D461/00
CPC分类号： C07D461/00
摘要： L'invention a pour objet de nouveaux dérivés du 14,15-dihydro 20,21 dinoréburnaméninl4-ol, de formule (I) dans laquelle R représente un radical -AR', dans lequel A représente un hétéroatome et R' représente un groupement choisi dans le groupe constitué par les radicaux alkyles en C 1 -C 6 , alcényles en C 1 -C 6 , alcynyles en C 1 -C 6 , aralkyles; les esters de formule - R 1 -CO-O-R 2 ; les amides de formule -R 3 -CO-NZY dans laquelle Y et Z peuvent former ensemble un radical cycloalkyle ou un radical hétérocyclique, éventuellement substitué par un ou plusieurs radicaux alkyles; un radical choisi dans le groupe constitué par les radicaux alkyles, alcényles ou alcynyles, substitués par au moins une amine de formule -NZY; ou l'un de ses sels pharmaceutiquement acceptables, y compris ses isomères, ses énantiomères, ses diastéréoisomères et leurs mélanges. L'invention a également pour objet l'utilisation de ces nouveaux dérivés pour la préparation d'une composition pharmaceutique, notamment destinée au traitement et/ou la prévention chez l'Homme des dépressions, des troubles du cycle veille-sommeil et des troubles symptomatiques frontaux dans leur composantes cognitives.
摘要翻译：本发明涉及具有式（I）的14,15-二氢20,21二辛烷亚胺-14-醇的新衍生物，其中R表示一个自由基-AR'，其中A表示杂原子，R'表示选自该基团包括C1-C6的烷基，C1-C6的烯基，C1-C6的炔基，芳烷基; 具有式-R1-CO-O-R2的酯; 具有式-R3-CO-NZY的酰胺，其中Y和Z一起可以形成任选被一个或多个烷基取代的环烷基或杂环基; 选自由至少一个具有式-NZY的胺取代的烷基，烯基或炔基的基团; 或其药学上可接受的盐之一，包括其异构体，对映体和非对映异构体及其混合物。本发明还涉及所述新型衍生物用于制备药物组合物的用途，该药物组合物特别用于治疗和/或预防人类中认知成分中的抑郁症，睡眠/觉醒周期障碍和症状性正面疾病。

10. 发明申请

WO2005082365A1 UTILISATION DU 14,15-DIHYDRO 20,21-DINOREBURNAMENIN14-OL POUR TRAITER ET/OU PREVENIR LES DEPRESSIONS MAJEURES ET LES DESORDRES DU CYCLE VEILLE-SOMMEIL 审中-公开
标题翻译：用于治疗和/或预防严重呕吐和休眠/排卵周期性疾病的14,15-二氢-20,21-多巴酚丁胺素-14-OL的用途
公开(公告)号：WO2005082365A1
公开(公告)日：2005-09-09
申请号：PCT/FR2005/000178
申请日：2005-01-27
申请人： BIOCORTECH , PUJOL, Jean-François , WEISSMANN, Dinah
发明人： PUJOL, Jean-François , WEISSMANN, Dinah
IPC分类号： A61K31/437
CPC分类号： A61K31/4375
摘要： L'invention a pour objet une nouvelle application thérapeutique du 14,15-dihydro 20,2 1 -dinoréburnaménin 1 4-ol pour le traitement des dépressions majeures chez l'Homme, notamment pour le traitement de patient résistant aux traitements antidépresseurs classiques, ou pour le traitement des désordres du cycle veille-sommeil.
摘要翻译：本发明涉及用于治疗人类严重抑郁症的14,15-二氢-2,2,2-dinoreburnamaminin-14-醇的新型治疗用途，特别是用于治疗耐常规抗抑郁药物治疗和治疗睡眠/唤醒循环障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式